Cart
sales@molnova.com
WHI-P180
CAS No. 211555-08-7
WHI-P180( Janex 3 )
Catalog No. M13366 CAS No. 211555-08-7
WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 44 | In Stock |
|
| 5MG | 40 | In Stock |
|
| 10MG | 61 | In Stock |
|
| 25MG | 129 | In Stock |
|
| 50MG | 184 | In Stock |
|
| 100MG | 291 | In Stock |
|
| 200MG | 434 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWHI-P180
-
NoteResearch use only, not for human use.
-
Brief DescriptionWHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
-
DescriptionWHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
-
In Vitro——
-
In VivoWHI-P180 is also an active inhibitor of IgE-mediated mast cell responses. The elimination half-life of WHI-P180 in CD-1 mice (BALB/c mice) following i.v., i.p., or p.o. administration is less than 10 min. Systemic clearance of WHI-P180 is 6742 mL/h/kg in CD-I mice and 8188 mL/h/kg in BALB/c mice. Notably, WHI-P180, when administered in two consecutive nontoxic i.p. bolus doses of 25 mg/kg, inhibits IgE/antigen-induced vascular hyperpermeability in a well-characterized murine model of passive cutaneous anaphylaxis.
-
SynonymsJanex 3
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK2| EGFR
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number211555-08-7
-
Formula Weight297.31
-
Molecular FormulaC16H15N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESOC1=CC=CC(NC2=C3C=C(OC)C(OC)=CC3=NC=N2)=C1
-
Chemical Name3-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An R, et al. Pharm Res. 2009 Feb;26(2):449-58.
molnova catalog
related products
-
JH-VIII-49
JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).
-
FMF-04-159-2
FMF-04-159-2 is a potent, selective, covalent CDK14 inhibitor (IC50=86 nM) with pan-TAIRE family specificity (CDKs 14-18).
-
JNJ-7706621
A dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM).
